Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
Top Cited Papers
Open Access
- 14 February 2020
- journal article
- editorial
- Published by Elsevier BV in The Lancet Oncology
- Vol. 21 (3), 335-337
- https://doi.org/10.1016/s1470-2045(20)30096-6
Abstract
No abstract availableKeywords
Funding Information
- China National Science Foundation (81871893)
- Key Project of Guangzhou Scientific Research (201804020030)
This publication has 10 references indexed in Scilit:
- A novel coronavirus outbreak of global health concernThe Lancet, 2020
- A pneumonia outbreak associated with a new coronavirus of probable bat originNature, 2020
- [Report of cancer epidemiology in China, 2015].2019
- Myeloid suppressor cells in cancer and autoimmunityJournal of Autoimmunity, 2017
- Features of Postoperative Immune Suppression Are Reversible With Interferon Gamma and Independent of Interleukin-6 PathwaysAnnals of Surgery, 2016
- Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung CancerJournal of Immunology Research, 2014
- Nosocomial infections in patients with cancerThe Lancet Oncology, 2009
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004